<div id="readability-page-1"><p>Friedenthal Financial acquired a new position in  10x Genomics (NASDAQ:TXG - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 79,033 shares of the company's stock, valued at approximately $924,000. Friedenthal Financial owned 0.06% of 10x Genomics at the end of the most recent quarter.</p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>Several other institutional investors also recently modified their holdings of TXG. Charles Schwab Investment Management Inc. raised its stake in shares of  10x Genomics by 20.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 648,410 shares of the company's stock valued at $5,661,000 after purchasing an additional 108,744 shares in the last quarter.  Invesco Ltd. increased its holdings in  10x Genomics by 62.1% in the 1st quarter. Invesco Ltd. now owns 191,332 shares of the company's stock valued at $1,670,000 after buying an additional 73,265 shares during the period.  Nuveen LLC acquired a new position in shares of  10x Genomics in the 1st quarter valued at $1,755,000.  Russell Investments Group Ltd. lifted its holdings in shares of  10x Genomics by 385.6% during the 1st quarter. Russell Investments Group Ltd. now owns 81,669 shares of the company's stock worth $713,000 after acquiring an additional 64,851 shares during the period.  Finally, AlphaQuest LLC lifted its holdings in shares of  10x Genomics by 8.3% during the 1st quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock worth $257,000 after acquiring an additional 2,258 shares during the period. Institutional investors and hedge funds own  84.68% of the company's stock. </p><h2>Insider Activity</h2><p>In related news, CEO Serge Saxonov sold 13,261 shares of the firm's stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $251,959.00. Following the transaction, the chief executive officer owned 1,021,556 shares in the company, valued at $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Adam Taich sold 11,888 shares of the business's stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the sale, the chief financial officer directly owned 297,385 shares of the company's stock, valued at $5,650,315. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,432 shares of company stock valued at $635,208. Company insiders own  10.03% of the company's stock. </p><h2>10x Genomics Trading Down 2.6%</h2><p>TXG opened at $16.50 on Wednesday. The stock has a market capitalization of $2.09 billion, a PE ratio of -26.61 and a beta of 2.15. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $20.34. The firm has a 50-day moving average price of $15.67 and a two-hundred day moving average price of $13.66. </p><p>10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million for the quarter, compared to analyst estimates of $142.50 million. 10x Genomics's quarterly revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) earnings per share.  On average, research analysts predict that  10x Genomics will post -1.43 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts recently issued reports on TXG shares. Morgan Stanley  reissued an &#34;equal weight&#34; rating and issued a $20.00 price target (up previously from $17.00) on shares of 10x Genomics in a research report on Monday, December 1st. Citigroup cut 10x Genomics from a &#34;buy&#34; rating to a &#34;cautious&#34; rating in a report on Thursday, December 11th. UBS Group raised their target price on 10x Genomics from $13.00 to $14.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, November 7th. Canaccord Genuity Group upped their price target on 10x Genomics from $19.00 to $20.00 and gave the company a &#34;buy&#34; rating in a research report on Monday. Finally, Barclays increased their price objective on 10x Genomics from $17.00 to $22.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating, nine have assigned  a Hold rating and three have assigned  a Sell rating to the stock. According to data from MarketBeat, 10x Genomics currently has an average rating of &#34;Hold&#34; and an average price target of $15.81.</p><p><b>View Our Latest Research Report on 10x Genomics</b></p><h2>10x Genomics Profile</h2> (Free Report)<p>10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.  </p><p>Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than 10x Genomics</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>Trump’s “real estate deal for America” explained</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Trump Did WHAT??</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2><p>Before you consider 10x Genomics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Friedenthal Financial acquired 79,033 shares of 10x Genomics, valued at $924,000, in Q3. Other institutional investors also increased their holdings. CEO Serge Saxonov and CFO Adam Taich sold shares. 10x Genomics reported Q3 revenue of $149M and a net loss of $0.22 per share. Analysts have mixed ratings on the stock.</p>

Friedenthal Financial Purchases New Holdings in 10x Genomics $TXG